Therefore, the presence of PD-1 on CAR-T cells and the presence of the PD-L1 ligand on NB cells are necessary for the checkpoint inhibitor to increase the therapeutic efficacy of CAR-T cells. The gene discussed is CD274; the disease is neuroblastoma.